Multidimensional radiotherapy for squamous cell cancer of the head and neck: New concept at the edge of clinical practice [Radioterapia wielowymiarowa raków płaskonabłonkowych regionu głowy i szyi: Nowa koncepcja u progu praktyki klinicznej]
Suwinski R.,Zaklad Radioterapii |
Snietura M.,Zaklad Patologii Nowotworow |
Jaworska M.,Zaklad Patologii Nowotworow |
Nikiel B.,Zaklad Patologii Nowotworow |
And 5 more authors.
Nowotwory | Year: 2011
Recent developments in cancer imaging, computerized treatment planning and therapeutic procedures resulted in a widespread shift towards conformal radiotherapy, in which the isodose distribution matches spatial dimensions of the tumor and dose-limiting structures. Conformal distribution of the physical dose does not, however, entail the conformality of treatment with respect to the biology of the tumor. Further progress in radiotherapy will be possible due to enhanced knowledge of key relationships between the expression of molecular markers and the clinical effect of combined treatment. Such perspective provides the basis for multidimensional radiotherapy, which accounts not only for spatial distribution of the physical radiation dose, but also for dose-time-fractionation, selection of systemic therapy and sequence of treatment, thus conforming to the individual biological characteristics of the tumor. The present report demonstrates the practical applications of multidimensional radiotherapy in the combined treatment for head and neck cancer, with reference to the studies performed in Gliwice, and to data from literature.
Bevacizumab in the 1st line treatment of triple negative metastatic breast cancer patient - Case report and review of the literature [Bewacyzumab w leczeniu pierwszej linii u chorej na potrójnie negatywnego raka piersi w stadium rozsiewu - opis przypadku i przegląd literatury]
Badora-Rybicka A.,Klinika Onkologii Klinicznej |
Kaleta B.,Klinika Onkologii Klinicznej |
Zarudzki L.,Zaklad Radiodiagnostyki i Diagnostyki Obrazowej |
Sikora-Jopek M.,Klinika Onkologii Klinicznej |
Nowara E.,Klinika Onkologii Klinicznej
Nowotwory | Year: 2014
Introduction. Angiogenesis and VEGF (vascular endothelial growth factor) overexpression play an important role in the growth and development of many kinds of cancers. The role of bevacizumab, humanised, anti-VEGF antibody, in treatment of patients with metastatic breast canser (MBC) is still an open question. The aim of this paper is to present a case report of the use of bevacizumab with chemotherapy in the frst line treatment of triple negative MBC. Case. We present the case of a 57-year-old woman with infltrating ductal carcinoma of the right breast (pT1N0M0, TNBC). She underwent wide excision of the tumour with the excision of right axillary lymph nodes, adjuvant che-moterapy and radiotherapy. Four years later metastases in the left lung (two lesions) and mediastinum occured. For this reason the patient started immunochemotherapy - paclitaxel and bevacizumab. She ended paclitaxel after nine cycles, and continued bevacizumab as a maintenance. We observed a marked decrease in size of the metatstatic lesions. No serious adverse events during treatment were noted. From October 2009 to September 2013 the patient received 70 doses of bevacizumab. In September 2013 the treatment was ended due to progression of the size of the lung metastases. No new site of metastases was noted. The patient was considered suitable for stereotactic radiosurgery.Discussion. To date three randomised, multicenter studies, which evaluated efectiveness of adding bevacizumab to chemotherapy were performed. In all trials signifcant prolongation of progression-free survival (PFS) was observed but with no statistically signifcant infuence on overall survival (OS). The toxicity of the combined treatment was higher. Many experts put a great emphasis on the need to discover a group of patients who will gain a signifcant beneft from antiangiogenic treatment. Reports in the literature indicate that probably the greatest beneft from adding bevacizumab to the chemotherapy is gained by women with triple-negative breast cancer, who receive bevacizumab as frst-line treatment after cancer progression, as our patient described above. © Polskie Towarzystwo Onkologiczne.